NCT00469235已完成1 期
A Single-centre, Double Blind, Randomised, Rising Dose Tolerance Study to Investigate the Safety of Juvista When Administered Following Excision of Ear Lobe Keloids.
Renovo1 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2007年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
- 试验地点
- 1
- 主要终点
- Frequency of adverse events
研究概览
简要总结
This trial will assess the safety and efficacy of 50 and 200ng Juvista per linear cm of wound margin administered by intradermal injection following the excision of keloid scars on the ear lobe. Ear lobe keloids commonly occur after ear piercing and can be particularly distressing for patients as they are very difficult to conceal and are usually bilateral. As the recurrence rate and growth rate of keloids can vary significantly between individuals, trial subjects will have bilateral ear lobe keloids and will act as their own control. One ear lobe will be treated with Juvista following keloid excision and one with placebo.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged 18-85 years who have given written informed consent.
- •Patients with bilateral ear lobe keloid scars suitable for surgical excision which will result in a single wound on each ear lobe no greater than 2cm long and restricted to the skin, fat and fibrous tissue of the ear lobe.
- •Patients with, in the opinion of the Investigator, clinically acceptable results for the laboratory tests specified in the trial protocol.
- •Female patients of child bearing potential who are using a highly effective method(s) of contraception and agree to do so from at least the screening visit until one month after administration of the final study dose.
排除标准
- •Patients who have had ear lobe keloids treated with irradiation, cryosurgery, corticosteroids, or other pharmacological agents in the three months prior to the first trial dose administration.
- •Patients with a history of a bleeding disorder.
- •Patients who on direct questioning and/or physical examination have past or present evidence of eczema or psoriasis local to the site of administration, uncontrolled diabetes (fasting plasma glucose concentration consistently at or above 7.0mmol 1-1 (126 mg dl-1), severely immunocompromised patients and/or malignant skin tumours e.g. melanomas, squamous or basal cell carcinomas.
- •Patients with a skin disorder, not related to the keloid disease, that is chronic or currently active and which the Investigator considers will adversely affect the healing of the acute wounds or involves the areas to be examined in this trial
- •Patients with a history of malignancy in the last 5 years.
- •Patients with a history of hypersensitivity to any of the drugs or dressings used in this trial.
- •Patients who are taking, or have taken any investigational product or participated in a clinical trial in the three months prior to first trial dose administration.
- •Patients undergoing investigations or changes in management for an existing medical condition.
- •Patients who, in the opinion of the Investigator, are unlikely to complete the trial for whatever reason.
- •Female patients who are pregnant or lactating.
- •Patients with a creatinine clearance (CLcr) of 80ml/min or less.
研究组 & 干预措施
1
Placebo Comparator
50ng dose group
干预措施: Avotermin (Drug)
2
Placebo Comparator
200ng dose group
干预措施: Avotermin (Drug)
结局指标
主要结局
Frequency of adverse events
时间窗: 3 months
次要结局
- Keloid reoccurrence(12 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Safety of Juvista When Administered Following Excision of Ear Lobe KeloidsKeloidNCT00710333Renovo10
已完成
1 期
Exploratory Study of the Efficacy and Safety of Juvista 250ng When Administered Following Excision of Ear Lobe KeloidsKeloidNCT00836147Renovo20
Unknown
2 期
Juvista (Avotermin) in the Prevention or Improvement of Scar Appearance Following Scar Revision Surgery.CicatrixNCT00432211Renovo60
已完成
3 期
Juvista in Scar Revision Surgery of Disfiguring ScarsCicatrixNCT00742443Renovo350
终止
2 期
Phase IIa Clinical Study of N-Rephasin® SAL200Staphylococcus Aureus BacteremiaAnti-Bacterial AgentsNCT03089697Intron Biotechnology, Inc.25